Panel-Gene Transcriptomic Associations and Published-Variant Architecture in Parkinson Disease
This study identifies significant transcriptomic changes in Parkinson disease but does not establish direct causal relationships or clinical implications.
Where it sits
this study against the rest of the glutathione (gsh) corpusSummary and findings
This study examined Parkinson disease (PD) using a 468-gene panel in four adult-brain GEO cohorts. The analysis identified 91 genes at Benjamini–Hochberg FDR < 0.05 and 56 high-confidence genes. Findings included higher abundance of selected iron-handling and stress-response transcripts, and lower abundance of selected glutathione-related transcripts.
Abstract
Abstract Parkinson disease (PD) was examined in four primary adult-brain GEO cohorts (GSE49036, GSE20141, GSE8397, GSE7621) using a frozen 468-gene redox, metal, xenobiotic, and barrier panel. Inverse-variance random-effects meta-analysis (DerSimonian–Laird) produced 419 analyzable genes, 91 at Benjamini–Hochberg FDR < 0.05, and 56 high-confidence genes (FDR < 0.05, measured in ≥ 3 cohorts, direction-concordant in ≥ 70% of cohorts, and nominally significant in ≥ 2 cohorts). Median I² among high-confidence genes was 16.4%. High-confidence calls included higher abundance of selected iron-handling and stress-response transcripts and lower abundance of selected glutathione- and mitochondrial-related transcripts. These are transcript-abundance findings; they do not themselves prove iron accumulation, glutathione depletion, or complex-I failure. A compiled variant inventory includes PD-relevant published alleles (including CYP2D6 poor-metabolizer and GST/PON1/ABCB1 pesticide-interaction literature). Expression and variant layers are not combined into a clinical score. GVI, DDI, and IDRS remain uncalibrated research formulae and are not used for inference in this paper. No statistical pooling with Alzheimer, ALS, multiple sclerosis, or autism cohorts was performed. This paper is a disease-restricted companion to the methods-and-panel manuscript of this series (1).
Background
This paper addresses the transcriptomic landscape of Parkinson disease (PD) by analyzing gene expression related to redox, metal handling, and xenobiotic response. Prior research has identified various genes associated with PD, but this study aims to clarify the specific transcriptomic changes in the disease. Understanding these changes may provide insights into the underlying biological mechanisms of PD.
Methods
The study utilized a frozen 468-gene panel and conducted an inverse-variance random-effects meta-analysis (DerSimonian–Laird) across four GEO cohorts. A total of 419 genes were analyzable, with a focus on identifying high-confidence genes based on specific statistical criteria. The analysis did not combine expression and variant data into a clinical score.
Results
The analysis produced 419 analyzable genes, with 91 genes showing significance at Benjamini–Hochberg FDR < 0.05. Among these, 56 high-confidence genes were identified, which were measured in at least three cohorts and showed direction-concordance in at least 70% of cohorts. The median I² among high-confidence genes was reported as 16.4%.
Interpretation
The findings indicate significant transcriptomic changes in PD, particularly regarding iron handling and stress response, while showing lower levels of glutathione-related transcripts. However, the effect sizes and their clinical relevance remain unclear, as the study does not provide direct clinical applications or implications. Additionally, the lack of statistical pooling with other neurological cohorts limits the generalizability of the findings.
Key findings
- 419 analyzable genes identified, n=4 cohorts.
- 91 genes at Benjamini–Hochberg FDR < 0.05.
- 56 high-confidence genes defined by FDR < 0.05, measured in ≥ 3 cohorts.
- Median I² among high-confidence genes was 16.4%.
Limitations
- Not a clinical trial, observational study design.
- Small sample size across four cohorts.
- No pooling with other neurological disease cohorts.
- Expression and variant data not combined into a clinical score.
- Findings are transcript-abundance based and do not prove causation.